X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (214) 214
clinical neurology (157) 157
index medicus (149) 149
multiple sclerosis (137) 137
neurosciences (126) 126
animals (107) 107
female (80) 80
neurology (76) 76
male (64) 64
multiple sclerosis - drug therapy (57) 57
adult (54) 54
immunology (53) 53
middle aged (44) 44
multiple-sclerosis (43) 43
experimental autoimmune encephalomyelitis (39) 39
multiple sclerosis - immunology (39) 39
natalizumab (39) 39
double-blind (37) 37
guillain-barre-syndrome (36) 36
treatment outcome (36) 36
immunologic factors - therapeutic use (35) 35
research (34) 34
guillain-barre syndrome (33) 33
mice (31) 31
medicine & public health (30) 30
therapy (30) 30
interferon-beta - therapeutic use (29) 29
multiple sclerosis, relapsing-remitting - drug therapy (29) 29
abridged index medicus (27) 27
drug therapy (27) 27
guillain-barré syndrome (26) 26
progressive multifocal leukoencephalopathy (26) 26
aged (25) 25
central-nervous-system (25) 25
mice, inbred c57bl (25) 25
rats (25) 25
cerebrospinal-fluid (24) 24
care and treatment (23) 23
nervous system (23) 23
antibodies, monoclonal - therapeutic use (22) 22
cells, cultured (22) 22
experimental autoimmune neuritis (22) 22
expression (22) 22
health aspects (22) 22
immunotherapy (21) 21
lymphocytes (21) 21
neurology. diseases of the nervous system (21) 21
placebo-controlled trial (21) 21
inflammation (20) 20
disease (19) 19
disease models, animal (19) 19
interferon beta (19) 19
pharmacology & pharmacy (19) 19
t-cells (19) 19
analysis (18) 18
autoimmunity (18) 18
cells (18) 18
immunosuppressive agents - therapeutic use (18) 18
myelin basic-protein (18) 18
pathogenesis (18) 18
risk factors (18) 18
antibodies (17) 17
clinical trials as topic (17) 17
cytokines (17) 17
experimental allergic neuritis (17) 17
magnetic resonance imaging (17) 17
neuroradiology (17) 17
t-lymphocytes - immunology (17) 17
demyelination (16) 16
diagnosis (16) 16
glatiramer acetate (16) 16
multiple sclerosis - physiopathology (16) 16
multiple sclerosis - therapy (16) 16
proteins (16) 16
t cells (16) 16
antibodies, monoclonal, humanized (15) 15
development and progression (15) 15
time factors (15) 15
autoimmune diseases (14) 14
disease progression (14) 14
guillain-barre syndrome - immunology (14) 14
mitoxantrone (14) 14
multifocal motor neuropathy (14) 14
allergy and immunology (13) 13
cidp (13) 13
clinical trials (13) 13
experimental allergic encephalomyelitis (13) 13
immunosuppression (13) 13
interferon (13) 13
interferon-beta (13) 13
medicine (13) 13
multiple sclerosis - pathology (13) 13
rodents (13) 13
young adult (13) 13
antibodies, monoclonal, humanized - therapeutic use (12) 12
antigens (12) 12
encephalomyelitis, autoimmune, experimental - immunology (12) 12
immunoglobulins, intravenous - therapeutic use (12) 12
in-vitro (12) 12
inflammatory demyelinating polyneuropathy (12) 12
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature Reviews Neurology, ISSN 1759-4758, 05/2011, Volume 7, Issue 5, pp. 255 - 262
Journal Article
Lancet Neurology, The, ISSN 1474-4422, 2014, Volume 13, Issue 3, pp. 234 - 235
  The monoclonal antibody natalizumab and fingolimod (the first approved oral multiple sclerosis therapy) are both effective, but associated with risks; most... 
Neurology | CLINICAL NEUROLOGY | ORAL FINGOLIMOD | Multiple Sclerosis, Relapsing-Remitting - drug therapy | Humans | Female | Male | Crotonates - administration & dosage | Multiple Sclerosis, Relapsing-Remitting - diagnosis | Toluidines - administration & dosage | Multiple sclerosis | Interferon | Drug therapy | Pharmaceutical industry | Immunotherapy
Journal Article
Multiple Sclerosis Journal, ISSN 1352-4585, 11/2019, p. 135245851988734
Background: There is an unmet need for precise methods estimating disease prognosis in multiple sclerosis (MS). Objective: Using advanced statistical modeling,... 
Journal Article
Neuroscience Letters, ISSN 0304-3940, 01/2018, Volume 662, pp. 136 - 141
Lysophosphatidic acid (LPA) is a pleiotropic signaling lipid that acts as ligand for at least six specific G-protein coupled receptors. Schwann cells (SC) are... 
Nerve injury | Schwann cell differentiation | Neuropathy | Lysophosphatidic acid | Demyelination | AM095
Journal Article
Neuroscience Letters, ISSN 0304-3940, 01/2018, Volume 662, p. 136
To access, purchase, authenticate, or subscribe to the full-text of this article, please visit this link: http://dx.doi.org/10.1016/j.neulet.2017.10.023... 
Analysis | Mice | Cell differentiation | Myelin proteins
Journal Article
Multiple Sclerosis Journal, ISSN 1352-4585, 7/2012, Volume 18, Issue 7, pp. 914 - 924
Journal Article
Multiple Sclerosis Journal, ISSN 1352-4585, 11/2019, p. 135245851988561
Background: Neurofilament light chain (NfL) is a promising marker of disease activity/treatment response in multiple sclerosis (MS), although its predictive... 
Journal Article
Multiple Sclerosis Journal, ISSN 1352-4585, 05/2019, p. 135245851984951
Journal Article
Neuropsychiatric Disease and Treatment, ISSN 1176-6328, 2009, Volume 5, Issue 1, pp. 333 - 340
In the light of new cases of progressive multifocal leukoencephalopathy and induced autoimmunity in multiple sclerosis (MS) patients who received treatment... 
Immunosuppressant | Oral drugs | Teriflunomide | Multiple sclerosis | teriflunomide | immunosuppressant | PSYCHIATRY | multiple sclerosis | CLINICAL NEUROLOGY | oral drugs
Journal Article
Expert Review of Neurotherapeutics, ISSN 1473-7175, 01/2014, Volume 14, Issue 1, pp. 105 - 120
Irreversible disability is the critical long-term consequence of multiple sclerosis (MS). While there are well-established measures for disability in MS, they... 
Journal Article
CNS Drugs, ISSN 1172-7047, 06/2011, Volume 25, Issue 6, p. 491
Multiple sclerosis (MS) is characterized by autoimmune inflammation and subsequent neurodegeneration. It is believed that early in the disease course,... 
Multiple sclerosis | Care and treatment | Interferon beta | Development and progression | Research | Health aspects | Risk factors
Journal Article
Nature Reviews Neurology, ISSN 1759-4758, 12/2011, Volume 7, Issue 12, pp. 659 - 660
Journal Article
Neurology, ISSN 0028-3878, 12/2014, Volume 83, Issue 23, pp. 2153 - 2157
Objective: To assess whether pretreatment-lymphocyte counts, treatment before fingolimod, age, sex, or body mass index (BMI) affects the risk of... 
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.